Mechanisms of acquired resistance and tolerance to egfr targeted therapy in non-small cell lung cancer

HIGHLIGHTS

• who: Houssein Chhouri et al. from the Univ Rouen Normandie, Inserm, NorDiC UMR, Rouen, France have published the paper: Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer, in the Journal: Cancers 2022, 14, x FOR PEER REVIEW of /2022/
• what: In this review the authors provide an overview of the currently available treatment options for NSCLC focusing on EGFR targeted therapy and discuss the common mechanisms of resistance to EGFR-TKIs. The phase III FLAURA study was designed to compare osimertinib to first generation EGFR-TKIs in . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.